Watchlist for February 25, 2008

Well the rumored bond insurer deal from late Friday hasn't happened (yet?). That makes me wonder if the market will give back those late Friday gains and sink back down to Friday's lows.

On Today's Calendar:

10:00 -- Existing Home Sales

More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic

Potential swing trades:

See one of the recent 'Chart Reading' posts for some potential swing candidates. Also be sure to check my typical swing trade entry & exit rules.

Potential day trades:

(From Briefing.com)

Gapping Down

In reaction to weak earnings/guidance: -2.5% AAUK... M&A news: ERTS -2.9% (proposes to acquire TTWO for $26/share in cash; TTWO rejected the bid)... Financials under pressure following cautious comments from Oppenheimer and Goldman: C -2.2%, BSC -1.8%, LEH -1.5%, BAC -1%, JPM -1%, MER -1%, WB -1%. Other news: GFI -3.7% (announces production effects after electricity crisis), BHP -2.8% (Heavy rainfall hits Queensland coal ops - DJ)... Analyst downgrades: SMSI -10.4% (downgraded to Neutral at JP Morgan), FRE -4.4%, FNM -3.9% WM -3.0% (all downgraded to Sell at Goldman), GM -2.4% (downgraded to Hold at Deutsche).

Gapping Up

In reaction to strong earnings/guidance: PWRD +8.0%, GRO +6.9%... M&A news: TTWO +48.9% (Electronic Arts proposes to acquire co for $26/share in cash; TTWO rejected the bid), GYI +31.7% (agrees to be acquired by Hellman & Friedman for $34.00 in cash)... Other news: GTXI +58.7% (says Toremifene Citrate 80 mg meets primary and key endpoints in phase iii trial in advanced prostate cancer patients on androgen deprivation therapy), DNA +8.2% (announces that FDA grants accelerated approval of Avastin in combination with paclitaxel chemotherapy for first-line treatment of advanced HER2-negative breast cancer), HOKU +7.9% (announces a securities purchase agreement with certain institutional investors, and a wholly owned subsidiary of Suntech Power Holdings), RBS +8.0% (stock traded higher in Europe on speculation that the Qatari govt was considering making an investment), DNDN +4.0% (strength potentially related to positive sentiment following DNA approval in breast cancer), COMV +2.9% (announces award of $67 mln demand side management contract with Con Edison)...